BioTuesdays

Category - Feature

Feature

Titan implanting treatments for opioid dependence

By Len Zehr In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a matchstick...

August 19, 2014
Feature

In conversation with Jason Mitakidis

By Len Zehr As president and CEO of closely held Cyclica, Jason Mitakidis first became interested in computer simulation or, in silico, drug discovery while he was working as a bioinformatician at the Barcode...

August 5, 2014
Feature

XTL hopes to begin major lupus trial next year

By Len Zehr XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are...

July 22, 2014
Feature

Medifocus readies marketing expansion of Prolieve

By Len Zehr Medifocus (OTCQX:MDFZF; TSX-V:MFS) is raising $6-million to $10-million to expand the sales and marketing of its minimally invasive Prolieve device as a treatment for benign prostatic hyperplasia (BPH), or...

July 8, 2014
Feature

Response Biomedical charting turnaround story

By Len Zehr The new management team of Response Biomedical (OTCBB:RPBIF; TSX:RBM), with the strong support of its controlling shareholder, OrbiMed Advisors, has adopted an aggressive plan to drive sales and achieve...

July 1, 2014
Feature

Enrollment in Athersys stroke trial nears completion

By Len Zehr Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients...

May 27, 2014